Expert Interview
A discussion on the chances of approval and market potential for KemPharm's (KMPH) KP201/Apadaz in short-term management of acute pain
Ticker(s): KMPHThe expert will be someone with significant experience in acute pain management and a deep knowledge of other available hydrocodone combination products such as Vicodin, Norco and Lortab.
Can you describe your experience in acute pain management and your knowledge of the other hydrocodone combination products, Vicodin, Norco and Lortab?
Added By: pjloriaCan you highlight the differences in labeling, data, and profiles of these drugs?
Added By: pjloriaGiven the current data, what are your thoughts and concerns regarding KP201?
Added By: pjloriaDo you agree that the KP201 formulation is abuse-deterrent?
Added By: pjloriaIf KP201 is abuse-deterrent, will doctors prescribe it more than Vicodin, Norco and Lortab?
Added By: pjloriaWhat percentage of new patients do you think will use KP201 if it is approved? What percentage will remain on Vicodin, Norco and Lortab?
Added By: pjloriaGiven the current data, what chance do you think KP201 has of being approved by the FDA?
Added By: pjloriaAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
- KemPharm (KMPH) Appeals FDA Complete Response Letter on Apadaz by Initiating a Formal Dispute Resolution Process KMPH Occurred On: Nov 03, 2016
- FDA Issues Complete Response Letter for Apadaz New Drug Application KMPH Occurred On: Jun 13, 2016
- KemPharm Files NDA Amendment Request with FDA for Apadaz Discussions On-going with FDA on Potential Apadaz Product Labeling KMPH Occurred On: Jun 09, 2016
- Statement Regarding FDA Advisory Committee Meeting on KemPharm’s Abuse-Deterrent Product Candidate Apadaz KMPH Occurred On: May 05, 2016
- FDA Grants Priority Review to KemPharm for KP201/Apadaz NDA; PDUFA set for June 9, 2016 KMPH Occurred On: Jun 13, 2016
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.